---
title: "Bemarituzumab Plus Chemo Improves OS in FGFR2b+ Gastric Cancer"
description: "Bemarituzumab plus chemotherapy improves survival in advanced gastric cancer, new study shows."
pubDate: "2025-06-30"
category: "business"
image: "https://cdn.sanity.io/images/0vv8moc6/targetedonc/5af6e25b17d074d8c9c8cb627adfc1e12de90596-480x270.png?fit=crop&auto=format"
slug: "bemarituzumab-plus-chemo-improves-os-in-fgfr2b-gastric-cancer"
source: "Targeted Oncology"
lang: "en"
---

New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options.

Gastric cancer cells: Â© LASZLO - stock.adobe.com
First-line treatment with bemarituzumab plus chemotherapy (mFOLFOX6) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) vs placebo plus chemotherapy... [2808 chars]

[Kaynak](https://www.targetedonc.com/view/bemarituzumab-plus-chemo-improves-os-in-fgfr2b-gastric-cancer)
